CHIP (clonal hematopoiesis of indeterminate potential) is a non-malignant condition characterized by mutational and clonal expansion of hematopoietic stem cells, beginning at middle age. CHIP is associated with a higher risk for several diseases including hematological malignancies, cardiovascular diseases and many others. Understanding the causes and mechanisms of CHIP and how these cells interact with cells of other tissues will provide critical insights into disease development and evolution.
In this panel discussion webinar, speakers discuss the growing interest in this topic and a few example studies looking at how this condition arises and transforms into a disease. Ross Levine, MD of Memorial Sloan Kettering Cancer Center (MSKCC) discusses the clinical manifestations of clonal hematopoiesis, and mechanisms underlying its development as well as its role in clonal evolution toward leukemia. Then he’s joined by two other speakers, Kelly Bolton MD, PhD of Washington University of St. Louis and Jyoti Nangalia, MD, PhD of Wellcome Sanger Institute, for an interactive panel discussion that will offer key insights and diverse perspectives on CHIP as an important risk factor and its clinical impact.